American Journal of Clinical Pathology · 2019 · 50 citations · 13 references
MedicineOncologyPathologyBreast OncologyMolecular OncologyNeoplasiaBreast Cancer OncologyHer2-positive Breast CancerMalignant NeoplasmsBreast Cancer Molecular SubtypesBreast Core Needle BiopsyHer2 AmplificationHer2 ExpressionHer2 Gene AmplificationHormone Receptor - Positive Breast CancerHuman Epidermal Growth Factor Receptor 2 (Her2) ExpressionInvasive Carcinoma Assessment
OBJECTIVES: The 2018 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) human epidermal growth factor receptor 2 (HER2) guideline focused update revises the HER2 scoring criteria. We evaluated the impact on HER2 rates in breast carcinoma diagnosed at our center. METHODS: In a retrospective series of breast core biopsies with invasive carcinoma diagnosed between 2014 and 2017 (n = 1,350), HER2 status was classified according to 2013 and 2018 ASCO/CAP guidelines and changes in HER2 status identified. RESULTS: The 2018 guidelines reclassified the HER2 status of 6% of patients. Most changed from HER2 equivocal status (equivocal by immunohistochemistry and fluorescence in situ hybridization under the 2013 guidelines) to HER2-negative status (2018 guidelines). The HER2-positive rate decreased by 0.4%. CONCLUSIONS: The 2018 guidelines decrease the rate of HER2 equivocal and positive breast cancer and reduce repeat HER2 testing on excision specimens. Approximately 0.4% of patients will become newly ineligible for anti-HER2 therapy.
13
Antonio C. Wolff, M. Elizabeth Hammond, David G. Hicks et al. · Journal of Clinical Oncology · 2013 · 4.1K citations · Full text
Antonio C. Wolff, M. Elizabeth Hammond, Kimberly H. Allison et al. · Journal of Clinical Oncology · 2018 · 2.5K citations · Full text
Michael F. Press, Guido Sauter, Marc Buyse et al. · Journal of Clinical Oncology · 2016 · 140 citations · Full text